Jump to content

SHA-68

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 21:53, 3 June 2016 (CS1 maintenance: vauthors/veditors or enumerate multiple authors/editors; WP:GenFixes on, using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

SHA-68
Clinical data
ATC code
  • none
Identifiers
  • N-[(4-fluorophenyl)methyl]-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H24FN3O3
Molar mass445.484 g/mol g·mol−1
3D model (JSmol)
  • c4ccccc4C1(c5ccccc5)OC(=O)N3C1CN(CC3)C(=O)NCc(cc2)ccc2F
  • InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)
  • Key:SFRQIPRTNYHJHP-UHFFFAOYSA-N
  (verify)

SHA-68 is a drug which acts as a selective, non-peptide antagonist at the neuropeptide S receptor NPSR. In animal studies it has anxiogenic effects, and blocks the stimulant action of neuropeptide S.[1][2]

See also

References

  1. ^ Fukatsu K, Nakayama Y, Tarui N, Mori M, Matsumoto H, Kurasawa O, Banno H. Bicyclic Piperazine Compound and Use Thereof. PCT Patent WO 2005/021555 A1. Published 26.08.2004
  2. ^ Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (June 2008). "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 893–901. doi:10.1124/jpet.107.135103. PMC 2583099. PMID 18337476.

Template:Neuropeptidergics